Larvol Delta - BioCryst-Announces-FDA-Acceptance-of-NDA-for-ORLADEYO-berotralstat-Oral-Granules-in-Patients-with-Hereditary-Angioedema-Aged-2-to-11-Years

Orladeyo (berotralstat) - BioCryst

https://www.globenewswire.com/news-release/2025/05/14/3080994/29446/en/BioCryst-Announces-FDA-Acceptance-of-NDA-for-ORLADEYO-berotralstat-Oral-Granules-in-Patients-with-Hereditary-Angioedema-Aged-2-to-11-Years.html

May 14, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next